Consequently, the inhibition of VEGF by bevacizumab can result in significant delays in wound repair by the evidence from both clinical observations and histopathological studies.[16] Previous studies have reported that the incidence of wound complications in brain tumor patients ranged from 10% to 35%.[17] The histopathology of bevacizumab-induced delaying wound healing has been explored in animal models and, to a lesser extent, in human patients. This evidence concerns the gene VEGFA and brain neoplasm.